Cytokeratin and vimentin expression in breast cancer

International Journal of Biological Markers

Volumn 24, Issue 1, 2009, Pages 38-46

  Vora, Hemangini H ^a   Patel, Nupur A ^a   Rajvik, Kruti N ^a   Mehta, Shalvi V ^a   Brahmbhatt, Birwa V ^a   Shah, Manoj J ^b   Shukla, Shilin N ^c   Shah, Pankaj M ^d  

^a Division of Immunohistochemistry and Flow Cytometry   (India)

^b Department of Pathology ^*  (India)

^c Medical Oncology and Hon Deputy Director Research and Education   (India)

^d GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

Author keywords

Breast cancer; Cytokeratin; Vimentin

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKERATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; VIMENTIN;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CARCINOMA IN SITU; CYSTOSARCOMA PHYLLOIDES; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; METASTASIS; MUCINOUS CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; TISSUE SECTION; TREATMENT RESPONSE;

EID: 67649961609     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2009.4965     Document Type: Article

References (21)

1. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-54.
2. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003; 15: 740-6.
3. Grünert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003; 4: 657-65.
4. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-84.
5. Nawshad A, LaGamba D, Hay ED. Transforming growth factor b (TGFb) signalling in palatal growth, apoptosis and epithelial mesenchymal transformation (EMT). Arch Oral Biol 2004; 49: 675-89.
6. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4: 540-50.
7. Eger A, Mikulits W. Models of epithelial-mesenchymal transition. Drug Discovery Today: Disease Models, 2005.
8. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelialmesenchymal transition: new insights in signaling, development, and disease. Cancer Res 2005; 65: 5991-5.
9. Guarino M, Rubino, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007; 39: 305-18.
10. Guarino M. Epithelial-mesenchymal transition and tumor invasion. Int J Biochem Cell Biol 2007; 39: 2153-60.
11. Sihto H, Lundin J, Lehtimaki T, et al. Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res 2008; 14: 4103-10.
12. Fuchs IB, Lichtenegger W, Buehler H, et al. The prognostic significance of epithelial mesenchymal transition in breast cancer. Anticancer Res 2002; 22: 3415-20.
13. Takei H, Iino Y, Horiguchi J, et al. Immunohistochemical analysis of cytokeratin 8 as a prognostic factor in invasive breast carcinoma. Anticancer Res 1995; 19: 1101-5.
14. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, et al. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 2005; 11: 8006-14.
15. Thomas PA, Kirschmann DA, Cerhan JR, et al. Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients. Clin Cancer Res 1999; 5: 2698-703.
16. Thompson EW, Paik S, Brünner N, et al. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 1992; 150: 534-44.
17. Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 1994; 31: 325-35.
18. Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn M. Vimentin is preferentially expressed in human breast carcinoma with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol 1990; 136: 219-27.
19. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 2005; 24: 7443-54.
20. Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008; 68: 989-97.
21. Planas-Silva, Waltz PK. Estrogen promotes reversible epithelial- to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 2007; 104: 11-21.